Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Two Weekly Administration of Intravenous Methoxy Polyethylene Glycol-epoetin Beta (MIRCERA) for the Treatment of Chronic Renal Anemia in Dialysis Patients Not Currently Treated With Erythropoietin-stimulating Agent (ESA).

NCT00737711 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00737711
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00737711 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Two Weekly Administration of Intravenous Methoxy Polyethylene Glycol-epoetin Beta (MIRCERA) for the Treatment of Chronic Renal Anemia in Dialysis Patients Not Currently Treated With Erythropoietin-stimulating Agent (ESA).
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2008
Completion date
October 31, 2009
Enrollment
189 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

anemia